Clarity strengthens Cu-64 network with new supply agreement
Filed with ASX · · 2 pages · English
• Agreement with SpectronRx ensures seamless supply of the diagnostic copper-64 (Cu-64 or Cu) isotope for Clarity’s products which continue to progress through clinical trials, including a pivotal Phase III clinical trial. • Cu-64 has an ideal 12.7-hour half-life that helps to overcome the overwhelming supply restraints of current-generation radiodiagnostics based on gallium-68 (Ga-68) with a half
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Complete response with Cu-67 SAR-bisPSMA
- Successful Completion of Retail Entitlement Offer
- Despatch of Retail Entitlement Offer Booklet
- Completion of Placement and Institutional Entitlement Offer
- Investor Presentation
Later from Clarity Pharmaceuticals
- Supply agreement for Ac-225 with TerraPower Isotopes
- FDA Fast Track Designation 64CU-SAR-bisPSMA
- S&P DJI Announces September 2024 Quarterly Rebalance
- SECuRE trial advances
- Shareholder briefing - presentation
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals